checkAd
    Startseite > Aktien > Vir Biotechnology > Nachrichten
    Vir Biotechnology
    Aktie
    ISIN: US92764N1028 WKN: A2PS0P SYM: VIR Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    9,7500
     
    USD
    -5,89 %
    -0,6100 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    14.06.24
    9,7400
     
    USD
    1.000 STK
    Briefkurs
    14.06.24
    9,7500
     
    USD
    2.700 STK

    Vir Biotechnology Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
    05.06.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    29.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
    29.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
    23.05.24 · Business Wire (engl.) · Vir Biotechnology
    Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
    22.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
    21.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
    02.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
    30.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    18.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
    11.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
    05.03.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
    23.02.24 · Business Wire (engl.) · Vir Biotechnology